Active — Not RecruitingPhase 3

Management of the PDA Trial

United States836 participantsStarted 2019-02-22

Plain-language summary

Estimate the risks and benefits of active treatment versus expectant management of a symptomatic patent ductus arteriosus (sPDA) in premature infants.

Who can participate

Age range48 Hours – 21 Days

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Mild, Moderate, or Severe Clinical Criteria with Small or Moderate size PDA on echocardiogram
✓. Mild or Moderate Clinical Criteria with Large PDA on echocardiogram

What they're measuring

Death or Bronchopulmonary Dysplasia (BPD) at 36 weeks PMA

Timeframe: birth to 36 week postmenstrual age

Trial details

NCT IDNCT03456336

SponsorNICHD Neonatal Research Network

Sponsor typeNETWORK

Study typeINTERVENTIONAL

Primary completion2025-03-02

View on ClinicalTrials.gov More Infant, Premature trials